Cerner and Qualcomm Collaborate to Advance Remote Home Health Monitoring

KANSAS CITY, Mo. and SAN DIEGO, April 13, 2015 (GLOBE NEWSWIRE) -- Cerner Corp. (Nasdaq:CERN) and Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated (Nasdaq:QCOM), today announced an agreement to extend Cerner's industry leading medical device connectivity capabilities beyond the hospital to the home. Cerner will leverage Qualcomm Life's FDA listed 2net(TM) Platform and Hub to seamlessly capture data from medical devices and sensors within a patient's home, and transmit it to Cerner health care clients through Cerner's

CareAware(R) device connectivity platform. Through this initiative, care providers can remotely monitor chronically ill patients in near real-time to enable proactive engagement to potentially reduce the risk of an acute care episode.

Qualcomm Life's 2net Platform collects, stores and aggregates patient data from connected medical devices provided to the patient, such as weight scales, blood pressure monitors and pulse oximeters. These data values will transmit via CareAware(R) to the Cerner Millennium(R) electronic health record (EHR) and is viewable to the patient in HealtheLife(SM), Cerner's patient engagement solution. Extending CareAware to integrate devices within the home to the patient's EHR will provide health care organizations a more comprehensive view in their efforts to focus on chronic condition management, reduce readmissions and improve patient health and satisfaction. The connected devices will be demonstrated in Cerner's booth (913) and Qualcomm Life's Ecosystem Pavilion (6420 in Hall B) at HIMSS15, the largest health information technology event in the industry, April 12 - 16 in Chicago, Ill.

"The industry is more concerned than ever about monitoring a patient's health outside the walls of the hospital through intelligently connected devices," said John Gresham, vice president of DeviceWorks, Cerner. "Cerner's CareAware device connectivity platform integrated with Qualcomm Life's technology will enable prescribable, turn-key monitoring capabilities that can be tailored to the needs of a person's chronic conditions across the care continuum, including the home."

Qualcomm Life will join Cerner's CareAware certification program, an initiative that creates alliances between Cerner and medical device manufacturers to better acquire data from devices to integrate with the EHR via CareAware device connectivity architecture.

"Our collaboration with Cerner will enable expanded reach of a scalable, remote patient monitoring (RPM) solution and is a step toward the realization of widespread population health management," said Rick Valencia, general manager and senior vice president, Qualcomm Life, Inc. "As the industry transitions from episodic care within acute care settings to continuous care, available away from the bedside, there is a need for a secure, medical-grade connectivity solution, which our 2net Platform provides."

Agnesian HealthCare is one of the first enterprise clients to implement this powerful combination of technologies to remotely monitor and manage at-risk patient populations.

"It is increasingly important that providers are monitoring the whole health of an individual, not just at the point of care in the facility," said Michael DeGeer, DPM, FACPS, FACFAS, vice president of Population Health Management, Agnesian HealthCare. "Remote Patient Monitoring allows our clinicians to have access to patients health data, within the patient's health record, while they are at home, which will provide the opportunity for clinicians to make informed interventions as needed."

 

About Cerner

Cerner's health information technologies connect people, information and systems at more than 18,000 facilities worldwide. Recognized for innovation, Cerner solutions assist clinicians in making care decisions and enable organizations to manage the health of populations. The company also offers an integrated clinical and financial system to help health care organizations manage revenue, as well as a wide range of services to support clients' clinical, financial and operational needs.

Cerner's mission is to contribute to the improvement of health care delivery and the health of communities. On February 2, 2015, Cerner Corporation acquired substantially all of the assets, and assumed certain liabilities, of the Siemens Health Services business from Siemens AG. (Nasdaq:CERN). For more information about Cerner, visit cerner.com, read our blog at cerner.com/blog, connect with us on Twitter at twitter.com/cerner and on Facebook at facebook.com/cerner.

Certain trademarks, service marks and logos set forth herein are property of Cerner Corporation and/or its subsidiaries. All other non-Cerner marks are the property of their respective owners.

 

About Qualcomm Incorporated

Qualcomm Incorporated (Nasdaq:QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated includes Qualcomm's licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of Qualcomm's engineering, research and development functions, and substantially all of its products and services businesses, including its semiconductor business, QCT. For more than 25 years, Qualcomm ideas and inventions have driven the evolution of digital communications, linking people everywhere more closely to information, entertainment and each other. For more information, visit Qualcomm's website, OnQ blog, Twitter and Facebook pages.

Qualcomm and 2net are trademarks of Qualcomm Incorporated, registered in the United States and other countries. 2net is a product of Qualcomm Life, Inc.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.